ATE511348T1 - Transgenes modell für morbus alzheimer - Google Patents

Transgenes modell für morbus alzheimer

Info

Publication number
ATE511348T1
ATE511348T1 AT05722229T AT05722229T ATE511348T1 AT E511348 T1 ATE511348 T1 AT E511348T1 AT 05722229 T AT05722229 T AT 05722229T AT 05722229 T AT05722229 T AT 05722229T AT E511348 T1 ATE511348 T1 AT E511348T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
transgene
transgenic
transgenic model
Prior art date
Application number
AT05722229T
Other languages
English (en)
Inventor
Lars Nilsson
Lars Lannfelt
Paer Gellerfors
Original Assignee
Bioarctic Neuroscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Neuroscience Ab filed Critical Bioarctic Neuroscience Ab
Application granted granted Critical
Publication of ATE511348T1 publication Critical patent/ATE511348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05722229T 2004-03-22 2005-03-17 Transgenes modell für morbus alzheimer ATE511348T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0400707A SE0400707D0 (sv) 2004-03-22 2004-03-22 Transgenic animal model
PCT/SE2005/000383 WO2005089539A1 (en) 2004-03-22 2005-03-17 Transgenic model for alzheimer’s disease

Publications (1)

Publication Number Publication Date
ATE511348T1 true ATE511348T1 (de) 2011-06-15

Family

ID=32067463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722229T ATE511348T1 (de) 2004-03-22 2005-03-17 Transgenes modell für morbus alzheimer

Country Status (10)

Country Link
US (1) US7709695B1 (de)
EP (1) EP1729569B1 (de)
JP (1) JP4914343B2 (de)
AT (1) ATE511348T1 (de)
AU (1) AU2005224992B2 (de)
CA (1) CA2560551A1 (de)
DK (1) DK1729569T3 (de)
ES (1) ES2367310T3 (de)
SE (1) SE0400707D0 (de)
WO (1) WO2005089539A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
CN102065881B (zh) 2008-04-14 2014-03-12 埃尔奇诺瓦公司 稳定的淀粉样beta单体和寡聚体
KR101634244B1 (ko) * 2014-06-19 2016-06-29 한경대학교 산학협력단 Talen을 이용하여 grk5 넉아웃 마우스를 제조하는 방법
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
EP3626832B1 (de) 2014-11-25 2024-06-12 The Brigham and Women's Hospital, Inc. Verfahren zur identifizierung einer person mit einer prädisposition für eine kardiometabolische krankheit oder eine davon betroffene person
EP3992292A4 (de) * 2020-02-28 2023-06-21 Rznomics Inc. Apoe4-rna-spezifisches transspleissungs-ribozym und dessen verwendung
CN113957095A (zh) * 2021-10-22 2022-01-21 江苏集萃药康生物科技股份有限公司 一种用于构建阿尔兹海默症动物模型的构建方法及其核酸组合物和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5455169A (en) 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
US5449604A (en) 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH07238035A (ja) * 1994-02-28 1995-09-12 Kyowa Hakko Kogyo Co Ltd βアミロイド蛋白質分解剤
US5777194A (en) 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
EP0920495B1 (de) 1996-07-24 2008-05-07 Novartis AG Transgentier-modell für die krankheit von alzheimer
US5898094A (en) 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
US20030131364A1 (en) 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7196163B2 (en) * 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
US20040248766A1 (en) 2001-06-18 2004-12-09 Andrea Leblanc Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
EP1563066A4 (de) 2002-11-04 2006-06-07 Bioarctic Neuroscience Ab Verfahren zur identifizierung von agentien, die die struktur und die prozessierung von beta-amyloid-vorläuferprotein modulieren
US20040255341A1 (en) * 2003-10-21 2004-12-16 Envivo Pharmaceuticals, Inc. Transgenic flies expressing Abeta42-Arctic

Also Published As

Publication number Publication date
US7709695B1 (en) 2010-05-04
DK1729569T3 (da) 2011-09-19
CA2560551A1 (en) 2005-09-29
WO2005089539A1 (en) 2005-09-29
EP1729569A1 (de) 2006-12-13
ES2367310T3 (es) 2011-11-02
JP2007530035A (ja) 2007-11-01
AU2005224992A1 (en) 2005-09-29
JP4914343B2 (ja) 2012-04-11
EP1729569B1 (de) 2011-06-01
SE0400707D0 (sv) 2004-03-22
AU2005224992B2 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
Wengenack et al. Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain
Spires et al. Transgenic models of Alzheimer’s disease: learning from animals
Radde et al. The value of incomplete mouse models of Alzheimer’s disease
IL154794A0 (en) Remedies for heart failure
SE0400707D0 (sv) Transgenic animal model
EA200702095A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их использования
WO2007149293A3 (en) Transgenic flies expressing tau and amyloid precursor fragment
Willuweit et al. Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease
Epis et al. Searching for new animal models of Alzheimer′ s disease
Garringer et al. Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice
ATE548453T1 (de) Material und methoden, involviert in die protein- aggregation neurodegenerativer krankheiten
WO2006052691A3 (en) Pet and magnetic resonance for screening alzheimer's disease therapeutics
Orta-Salazar et al. Morphological analysis of the hippocampal region associated with an innate behaviour task in the transgenic mouse model (3xTg-AD) for Alzheimer disease
Lee et al. Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein
ATE541923T1 (de) Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
JP2005512550A5 (de)
Zeng et al. Faithful expression of living color reporter genes in transgenic medaka under two tissue‐specific zebrafish promoters
EP1688036A4 (de) Transgenes nichthumanes säugetier
ATE323408T1 (de) Transgenes tiermodell für neurodegenerative erkrankungen
WO2003093442A3 (en) Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy
WO2005094571A1 (ja) 遺伝子改変ヘテロ動物及び該動物を用いたエキソサイトシスの計測方法
Wittnam The contribution of N-terminally modified amyloid beta to the etiology of Alzheimer's disease
IL174726A (en) Non-human animals with transgenic nucleic acid encoded by a mutant perinylin 1 protein
WO2004062627A3 (en) In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders
ATE460673T1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1729569

Country of ref document: EP